Calliditas Experiences Strong Q4 Growth, Looks to Expand in the Future

Calliditas Reports Strong Q4 Growth, Sets Sights on Expansion

Stockholm-based biopharmaceutical company Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) has announced significant growth in its fourth-quarter revenue, positioning the company for future expansion. With preliminary net revenue for its flagship product TARPEYO between $31 million and $33 million, Calliditas has experienced a substantial increase from its third-quarter performance. These strong fourth-quarter results have also contributed to Calliditas reporting preliminary net TARPEYO revenues for the full year of 2023, estimated to be between $100 million and $102 million, representing an impressive 170% increase from the previous year.